MAPT and Alzheimer disease: According to the results of a recent study, developing disease-modifying therapies to stop the spread of pathological proteins in PD and Alzheimer’s disease (AD) may benefit from focusing on particular tau and aSyn variants with elevated post translational modification (PTM), such as pS129 aSyn and C-terminus epitopes [33].